Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

NCT06176196 ↗

Phase 2 Completed 218 enrolled Vertex Pharmaceuticals Incorporated

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.

Timeline

Start: 2023-12-13
Primary completion: 2024-10-02
Completion: 2024-10-16

Outcome

Met primary endpoint

release “in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint” vrtx.com ↗

release “suzetrigine in painful lumbosacral radiculopathy (LSR), a form of peripheral neuropathic pain. The study met its primary endpoint” vrtx.com ↗

Publications

Siddiqui A, Xu JL, Abramowicz AE. Suzetrigine for the Treatment of Acute Pain: Comment. Anesthesiology. 2026 Feb 1;144(2):495-496. doi: 10.1097/ALN.0000000000005822. Epub 2025 Dec 11. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Suzetrigine	Small molecule	—	Oral